Q-omics provides the consensus-scored FAM66E profile across patient tissues and cancer cell-line models. FAM66E expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, FAM66E is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, FAM66E RNA expression shows 13,246 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCEC, KIRC, and THYM as cancer lineages where FAM66E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM66E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM66E survival associations across molecular data types. FAM66E RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM66E RNA expression–survival associations across cancer types. High FAM66E expression shows unfavorable associations in UCEC, LUSC and UVM, but favorable associations in PAAD, ACC and LGG. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for FAM66E RNA expression.
This table summarizes FAM66E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM66E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM66E shows lower tumor expression in KIRC, UCEC, KICH and BRCA and higher tumor expression in KIRP and CHOL. The KIRC box plot shows higher FAM66E RNA expression in normal versus tumor tissue (log2 FC = −0.035, t-test p < 0.001).
This table shows molecular features associated with FAM66E in patient tissues and cancer cell lines. In patient samples, FAM66E shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
